Eocene and Barcode Nanotech Report Progress in the Development of Tumor Microenvironment-Targeted Lipid Nanoparticles Formulation of Aramchol
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eocene (EOCN) and Barcode Nanotech have developed a lipid nanoparticle formulation of Aramchol intended to target liver and gastrointestinal tumors. The work runs through Eocene’s wholly owned subsidiary, Galmed Research & Development, using Barcode’s tumor-targeting delivery platform and FDA-approved lipids.
The formulation aims to redirect Aramchol to the tumor microenvironment, the tissue and cells surrounding cancer, and selectively inhibit cells that drive fibrosis. Eocene believes this approach could improve responses to immunotherapy and other standard treatments; those benefits remain potential. Earlier studies of oral Aramchol, including the randomized, placebo-controlled phase IIb ARREST trial and an open-label extension of the phase III ARMOR study, demonstrated improved liver fibrosis in patients with NASH/MASH, rather than results for the new cancer-targeted formulation.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointOral Aramchol improved liver fibrosis in NASH/MASH patients in phase IIb ARREST and the phase III ARMOR open-label extension.
- Minor pointAramchol lipid nanoparticle formulation developed through Galmed’s collaboration with Barcode Nanotech, using FDA-approved lipids.
- Minor point. Forward-looking: it has not happened yet and may not happen.Galmed aims to enhance and accelerate Aramchol’s antifibrotic effect by targeting the tumor microenvironment.
Negative
- None.
Key Terms
lipid nanoparticles technical
biodistribution medical
tumor microenvironment medical
placebo-controlled medical
immune checkpoint inhibitors medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- A unique proprietary lipid nanoparticles (LNPs) novel formulation of Aramchol has been developed using FDA-approved Lipids
- The novel formulation is designed to redirect Aramchol's biodistribution to target tumor microenvironment (TME) in liver and GI tumors and selectively inhibit the activity of cells that drive fibrosis
- By selectively targeting TME cells that drive fibrosis, the Aramchol LNP treatment could make immunotherapy and other standard of care liver and GI cancer therapies, work better for more patients with minimal toxicity
GIVATAYIM,
The TME is a complex network of immune cells, blood vessels and fibroblasts that interacts with cancer cells to facilitate tumor growth progression and hamper therapy responsiveness. While current cancer therapies such as immune checkpoint Inhibitors (Keytruda, Opdivo) and angiogenesis inhibitors (Avastin- anti-VEGF) address immune cells and blood vessels formation in TME, the Company is not aware of any approved therapy that targets fibrosis to remodel the TME.
As previously announced, in a randomized, double-blind, placebo-controlled phase IIb trial (ARREST) and an open label extension of a phase III study (ARMOR), orally formulated Aramchol demonstrated improvement in liver fibrosis in patients with NASH/MASH.
By employing the Barcode's existing tumor-targeting LNP formulation, Galmed aims to enhance and accelerate the antifibrotic effect observed with the oral formulation by redirecting Aramchol's biodistribution to target tumor microenvironment (TME).
Allen Baharaff, President and Chief Executive Officer of Eocene, commented: "Liver and other cancers often arise in fibrotic tissue as a result of chronic disease. Fibrosis creates an environment that suppresses immune cells and protects the tumor from the immune system and immunotherapy. Immunotherapy can initially elicit significant therapy responses which diminish for many patients, and we believe the fibrotic barrier is a key contributor. We believe Aramchol's novel LNP treatment could potentially make immunotherapy and other standard of care for liver and GI cancer therapies, work better for more patients for longer time and better results."
Ronen Eavri, Chief Executive Officer of Barcode-Nanotech, commented: "Building on our earlier work with Galmed to deliver Aramchol to the brain and the heart, we are now applying our proprietary lipid library and in vivo, AI-based screening platform, including our tumor-targeting LNP technology, to the development of an Aramchol LNP formulation directed to the tumor microenvironment of liver and GI cancers. By selectively reaching the cells that drive fibrosis, we hope to help immunotherapy and other standard-of-care treatments work for more patients."
About Eocene (formerly Galmed Pharmaceuticals)
Eocene Ltd. (NASDAQ: EOCN) is a GI-focused medtech and biopharmaceutical company headquartered in Givatayim,
About Barcode Nanotech Ltd.
Barcode Nanotech develops delivery solutions for RNA & DNA therapies through a unique multiplexed discovery platform. The Company's proprietary NeoRNA™ Targeting Technology enables efficient discovery and optimization of lipid-based nanoparticles (LNPs) through in silico & in vivo mass-screening. The solution combines the design of thousands of new lipids and LNPs, advanced AI tools and in vivo barcoding-based biodistribution analysis at a single cell resolution. Using this platform, Barcode has developed unique LNPs that can direct RNA and other therapies to tumors and to cells in the brain, kidney, lungs and additional target organs. Barcode has an in-house lead drug development program and concurrently collaborates with biopharma companies to develop new therapies.
For more information, visit www.eocn.com and www.barcode-nano.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to: the design, potential benefits and therapeutic potential of the Aramchol LNP formulation, including its potential to redirect Aramchol's biodistribution to the tumor microenvironment, inhibit cells that drive fibrosis and enhance the effectiveness of immunotherapy and other standard-of-care therapies for liver and GI cancers; the progress, timing and results of preclinical research and any future clinical development of the Aramchol LNP formulation; the continuation and success of the collaboration between Galmed and Barcode Nanotech; the potential evaluation of Aramchol in oncology indications; the potential benefits of CG-100 and the progress and results of Colospan's ongoing U.S. pivotal study of CG-100; the timing, extent and potential generation of future revenues; the expected benefits arising from the acquisition of Colospan; the Company's ability to execute its strategy and growth initiatives, including using its existing capital resources; and the Company's future business, operations, financial condition, prospects and objectives. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the risk that preclinical results may not be predictive of results in humans; the risk that the Aramchol LNP formulation may not achieve its intended biodistribution, safety or efficacy, or may not advance into clinical development; the risk that the collaboration with Barcode Nanotech may be delayed, modified or terminated; our inability to recognize the anticipated benefits of the acquisition of Colospan; expectations with respect to future performance and growth of Colospan; the development and approval of the use of Aramchol or any other product candidate for indications outside of non-alcoholic steatohepatitis, or NASH, also known as metabolic dysfunction-associated steatohepatitis, or MASH, and fibrosis or in combination therapy; the timing and cost of any pre-clinical or clinical trials of CG-100, Aramchol or any other medical device or product candidate we develop; completion and receiving favorable results of any pre-clinical or clinical trial; regulatory action with respect to CG-100, Aramchol or any other medical device or product candidate by the U.S. Food and Drug Administration, or the FDA, or the European Medicines Agency, or EMA, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; the commercial launch and future sales of CG-100, Aramchol and any future medical devices or product candidates; our ability to comply with all applicable post-market regulatory requirements for CG-100, Aramchol, or any other medical device or product candidate in the countries in which we seek to market the product; our ability to achieve favorable pricing for CG-100, Aramchol, or any medical device or other product candidate; third-party payor reimbursement for CG-100, Aramchol, or any other medical device or product candidate; our estimates regarding anticipated capital requirements and our needs for additional financing; market adoption of CG-100 Aramchol or any other medical device or product candidate by physicians and patients; the timing, cost or other aspects of the commercial launch of CG-100, Aramchol or any other medical device or product candidate; our ability to obtain and maintain adequate protection of our intellectual property; the possibility that we may face third-party claims of intellectual property infringement; our ability to manufacture our CG-100 or product candidates in commercial quantities, at an adequate quality or at an acceptable cost; our ability to establish adequate sales, marketing and distribution channels; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; our expectations regarding licensing, acquisitions and strategic operations; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; our ability to maintain the listing of our ordinary shares on The Nasdaq Capital Market; and the security, political and economic instability in the Middle East that could harm our business, including due to the current security situation in Israel. We believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in our Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on March 31, 2026 in greater detail under the heading "Risk Factors" and the additional risk factors relating to the business of Colospan Ltd. in the section entitled "Risk Factors" in our Report on Form 6-K filed with the SEC on June 8, 2026. Given these uncertainties, you should not rely upon forward-looking statements as predictions of future events. All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified in their entirety by the cautionary statements included in this press release. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by law. In evaluating forward-looking statements, you should consider these risks and uncertainties.
View original content to download multimedia:https://www.prnewswire.com/news-releases/eocene-and-barcode-nanotech-report-progress-in-the-development-of-tumor-microenvironment-targeted-lipid-nanoparticles-formulation-of-aramchol-302940359.html
SOURCE Eocene
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.